"Sodium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity.
| Descriptor ID |
D026941
|
| MeSH Number(s) |
D27.505.519.562.750 D27.505.954.411.720
|
| Concept/Terms |
Sodium Channel Blockers- Sodium Channel Blockers
- Sodium Channel Inhibitors
- Channel Inhibitors, Sodium
- Inhibitors, Sodium Channel
- Channel Blockers, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Sodium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Sodium Channel Blockers".
This graph shows the total number of publications written about "Sodium Channel Blockers" by people in this website by year, and whether "Sodium Channel Blockers" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 5 | 1 | 6 |
| 1998 | 2 | 5 | 7 |
| 1999 | 3 | 2 | 5 |
| 2000 | 5 | 1 | 6 |
| 2001 | 0 | 6 | 6 |
| 2002 | 3 | 3 | 6 |
| 2003 | 0 | 8 | 8 |
| 2004 | 3 | 5 | 8 |
| 2005 | 2 | 4 | 6 |
| 2006 | 4 | 5 | 9 |
| 2007 | 0 | 3 | 3 |
| 2008 | 3 | 4 | 7 |
| 2009 | 1 | 9 | 10 |
| 2010 | 4 | 10 | 14 |
| 2011 | 3 | 9 | 12 |
| 2012 | 2 | 6 | 8 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 4 | 4 |
| 2015 | 3 | 3 | 6 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
Below are the most recent publications written about "Sodium Channel Blockers" by people in Profiles.
-
An overview of drug-induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety. Clin Transl Sci. 2024 Dec; 17(12):e70098.
-
Rate-dependent effects of state-specific sodium channel blockers in cardiac tissue: Insights from idealized models. J Theor Biol. 2023 09 21; 573:111595.
-
Early recognition of characteristic conventional and amplitude-integrated EEG patterns of seizures in SCN2A and KCNQ3-related epilepsy in neonates. Seizure. 2023 Aug; 110:212-219.
-
The Utility of Sodium Channel Provocation in Unexplained Cardiac Arrest Survivors and Electrocardiographic Predictors of Ventricular Fibrillation Recurrence. Circ Arrhythm Electrophysiol. 2022 12; 15(12):e011263.
-
Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications. Brain. 2022 09 14; 145(9):2991-3009.
-
Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop. Neuromuscul Disord. 2021 06; 31(6):546-550.
-
Late INa Blocker GS967 Supresses Polymorphic Ventricular Tachycardia in a Transgenic Rabbit Model of Long QT Type 2. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e006875.
-
Topical Application of ASN008, a Permanently Charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset, and Long Duration of Action in a Mouse Model of Pruritus. J Pharmacol Exp Ther. 2020 09; 374(3):521-528.
-
Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle Nerve. 2020 10; 62(4):430-444.
-
Electrocardiological effects of ranolazine and lidocaine on normal and diabetic rat atrium. J Interv Card Electrophysiol. 2021 Apr; 60(3):387-394.